Industry says failure to consider new ways of assessing the value of drugs, including outcomes-based approaches and the use of real world evidence, represents a missed opportunity to promote sustainability of Europe’s healthcare systems
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.